Marshall Wace
PCVX icon

Marshall Wace’s Vaxcyte PCVX Stock Holding History

Marshall Wace’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-91,198
Closed -$5.73M – 2717
2023
Q4 		$5.73M Sell
91,198
-36,490
-29% -$1.9M 0.01% 867
2023
Q3 		$6.51M Sell
127,688
-422,678
-77% -$20.9M 0.01% 781
2023
Q2 		$27.5M Buy
550,366
+212,611
+63% +$10.1M 0.05% 374
2023
Q1 		$12.7M Buy
337,755
+15,155
+5% +$643K 0.03% 627
2022
Q4 		$15.5M Buy
+322,600
New +$12.7M 0.03% 577
2021
Q1 		– Sell
-14,426
Closed -$383K – 2766
2020
Q4 		$383K Sell
14,426
-9,027
-38% -$336K ﹤0.01% 1590
2020
Q3 		$1.16M Buy
+23,453
New +$934K 0.01% 976

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace's PCVX Position: Q1 2024 in Review

Marshall Wace sold out of Vaxcyte (PCVX) in Q1 2024, closing a stake of 91,198 shares — an estimated $5.73M sold.

Marshall Wace first reported a position in PCVX in Q3 2020 and held it in 7 quarters. The position peaked at $27.5M in Q2 2023. 251 funds tracked by Wall St. Rank hold PCVX as of Q1 2024.

  • Marshall Wace reported no remaining Vaxcyte position as of Q1 2024 after selling out during the quarter.
  • Marshall Wace sold 91,198 Vaxcyte shares in Q1 2024, an estimated $5.73M.
  • Marshall Wace first reported a position in Vaxcyte in Q3 2020 and held it in 7 quarters.
  • Marshall Wace's Vaxcyte position peaked at $27.5M in Q2 2023.
  • 251 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2024.

Based on Marshall Wace's 13F filing for Q1 2024, filed 15 May 2024.